Subtle signs of skin cancer you shouldn't ignore When the weather gets warmer and daylight hours longer, people are more likely to spend time outdoors in the sun. This also means there’s an increased ...

One researcher explains the science behind Lymphir, recently approved by the FDA for relapsed/refractory cutaneous T-cell lymphoma. The recent approval by the Food and Drug Administration (FDA) of ...

Nate, 55, a smoker, has seen three dermatologists for a rash that seems to be resistant to various treatments. He has complained that he has had a chronic bumpy and painful rash with pustules ...

World Lymphoma Awareness Day 2025 highlights the importance of recognizing early warning signs of lymphoma such as swollen ...

HUNTINGTON BEACH, California — When patients of Aaron Mangold, MD, first learn they have mycosis fungoides (MF), the most common form of primary cutaneous T-cell lymphoma (CTCL), some are concerned ...

Early skin changes, like unexplained rashes or bruises, can sometimes signal blood cancers such as leukemia and lymphoma.

The US Food and Drug Administration has approved denileukin diftitox-cxdl (Lymphir, Citius Pharmaceuticals) for adults with relapsed or refractory stage 1-3 cutaneous T-cell lymphoma after at least ...

Spreading awareness about lymphoma on World Lymphoma Awareness Day is important, as spotting the disease early and starting ...

Relapsed or refractory cutaneous t-cell lymphoma can be treated in adults with the new FDA approval of denileukin diftitox immunotherapy. The FDA announced their approval of deileukin diftitox-cxdl ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab-treated patients with AD were 4.1003 times more likely to develop cutaneous T-cell lymphoma vs. those ...

The anti-inflammatory medication dupilumab, marketed as Dupixent, is the subject of a lawsuit alleging a link between the use ...

Cutaneous vasculitis in primary Sjögren disease increases lymphoma risk, with type II cryoglobulinemic vasculitis linked to ...